US company COVAXX has announced $2.8bn advanced purchase commitments of over 140 million doses of its UB-612 vaccine to be delivered in countries including Brazil, Ecuador and Peru.
UB-612 is a multitope synthetic peptide vaccine that can potentially activate both B and T-cell arms of the immune system.
Go deeper with GlobalData
The latest development follows the initiation of human trials in Taiwan.
Also, Covaxx signed a deal with Brazilian clinical diagnostic firm Diagnosticos da America in September to conduct Phase II / III trials and distribute vaccines within Brazil.
The Phase I trials of UB-612 are nearing completion in Taiwan and the company made a deal with the University of Nebraska Medical Center (UNMC) to conduct trials in the US.
The company will also initiate Phase II / III clinical trials by the end of this year or first half of next year in Asia, Latin America and the US.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCOVAXX co-founder and CEO Mei Mei Hu said: “In parallel with the expedited clinical development of UB-612, we are working to help countries with the greatest unmet needs customise their plans for vaccine studies, supply and distribution.”
Last month, the company entered into a global logistics partnership with shipping and integrated logistics provider Maersk for enabling transportation and supply chain services for delivering UB-612 globally.
COVAXX co-founder and vice-chairman Dr Peter Diamandis said: “Our vaccine has the following key attributes that make it potentially best in class: First, it is boostable. Covid-19 is not ‘one and done’ and populations will likely require boosters to protect against the virus.
“Second, the vaccine is stable at 2-8C and can be delivered via existing distribution infrastructure and normal refrigeration; Third, from preliminary data, UB-612 has observed minimal reactogenicity (i.e. no fevers, chills or systemic issues).”
In addition, COVAXX’s manufacturing facilities are well-positioned to produce 100 million doses in the first half of next year and up to one billion by next year-end.
